Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label tasurgratinib trial in FGFR2 fusion cholangiocarcinoma
jRCT2080225052Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tasurgratinib in cholangiocarcinoma (CCA), sponsored by Eisai Co., Ltd. Started Feb 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2080225052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225052.